Taysha Gene Therapies (TSHA) Depreciation and Depletion (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Depreciation and Depletion of $300000.0 for Q1 2026, little changed on a YoY basis from $300000.0 in Q1 2025, and little changed sequentially from $300000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Depreciation and Depletion data on file, last reported at $300000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation and Depletion changed 0.0% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 8.64% YoY), and the FY2025 full-year result was $1.1 million, down 11.65% from the prior year.
- Depreciation and Depletion was little changed at $300000.0 in Q1 2026, from $300000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $400000.0 in Q2 2023 to a low of $200000.0 in Q3 2025.
- A 5-year average of $309235.3 and a median of $300000.0 in 2022 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion jumped 712.5% in 2022 and slumped 33.33% in 2025, its largest moves.
- Tracing TSHA's Depreciation and Depletion over 5 years: stood at $362000.0 in 2022, then increased by 10.5% to $400000.0 in 2023, then retreated by 24.0% to $304000.0 in 2024, then fell by 1.32% to $300000.0 in 2025, then changed by 0.0% to $300000.0 in 2026.
- Business Quant data shows TSHA's Depreciation and Depletion at $300000.0 in Q1 2026, $300000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | - |
| 10 | Taysha Gene Therapies | 2.07 Bn | 2.07 Bn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 304,000.00 |
| Dec 31, 2024 | 304,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |